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Abstract: Successful gene delivery to skeletal muscle is a desirable goal, not only for 
treating muscle diseases, but also for immunization, treatment of metabolic disorders, and/or 
delivering gene expression that can treat systemic conditions, such as bone metastatic cancer, 
for example. Although naked DNA uptake into skeletal muscle is possible, it is largely 
inefficient in the absence of additional chemical or physical delivery methods. We describe 
a system for delivery of non-viral or plasmid DNA to skeletal muscle using ultrasound-assisted 
sonoporation of a nanoplex combining plasmid DNA and a branched polymer based on 
poly(cyclooctene-graft-oligopeptide). The materials and methods described herein promise 
to advance the field of sonodelivery and of gene delivery to muscle for therapeutic 
applications since a simple system is presented that enables long-term gene expression in vivo 
with the promise of a minimal inflammatory gene expression profile. 
Keywords: sonodelivery; episome; polymer; nanoplex; microbubbles; non-viral vector; 
skeletal muscle; sustained expression; luciferase  
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1. Introduction 
Successful gene delivery to skeletal muscle is a desirable goal, not only for treating muscle diseases, 
but also for immunization, and/or delivering gene expression for treating systemic conditions such as 
bone metastatic cancer or metabolic disorders. Although naked DNA uptake into skeletal muscle is 
possible, it is largely inefficient in the absence of additional chemical or physical delivery methods. We 
have recently described a system for delivering plasmid DNA to skeletal muscle using ultrasound-assisted 
sonoporation (sonodelivery) of a nanoplex which combines plasmid DNA and a branched polymer, 
poly(cyclooctene-graft-oligopeptide) [1,2].  
In the present report, our main objective was to examine the potential for long-term expression of an 
episomal vector in skeletal muscle following sonodelivery. We utilized a plasmid that is capable of  
long-term maintenance within cells as an episomal vector. Episomal vectors are extra chromosomal 
eukaryotic vectors that represent a promising alternative to traditional viral gene therapy vectors, which 
typically require integration into the host genome to provide long-term gene expression. Episomes avoid 
insertional mutations that may be caused by integration events into the host genome. The precursor to 
the vector utilized in our study was first described as pEPI-1, a nonviral and episomally-replicating 
vector [3]. pEPI-1 was maintained episomally due to an active transcription unit which was linked to a 
scaffold/matrix attachment region, also known as S/MAR or MARS. MARS regions take part in forming 
chromatin domains and function as an origin of replication support. MARS can aid in the efficient 
retention of episomes and also transgene expression in mammalian cells. pEPI replicates autonomously 
in various cell lines, even in the absence of selective pressure. However, it has a limited use in gene 
therapy due to its low efficiency establishing itself as a replicating episomal entity soon after delivery 
into the targeted cells—nearly all plasmids are lost during ensuing cell division, and therefore few of  
the originally transfected vector molecules are capable of replicating episomally in a stable manner.  
One successful example of a modified pEPI is the vector pEPI-eGFP. Studies have shown that changes 
in chromatin state of the host, as well as of the vector, cause changes in episomal gene activity and 
influences the episome’s distributions into nuclear compartments. Therefore, episomal genes are subject 
to control systems of the host, as is shown for their equivalents in the host genome. The vector we utilized 
in the present report has been shown to be a very effective version of pEPI. This is the pEPIto, a vector 
with several modifiable regions, providing flexibility in experimental design and therapeutic gene 
expression profile. The prolonged transgene expression profiles of pEPito-based vectors in vivo appears 
to result from a combination of reduced epigenetic silencing due to the modified bacterial vector 
backbone, and the MARS region, which might either trigger the translocation of vector molecules to 
sites of active chromatin, or enhance overall transcription levels [4].  
Episomal vectors based on pEPI are continuously being refined and we envision that episomally 
replicating vectors will have applications for replicating in a tissue specific manner. For example, the 
human AFP-promoter, combined with the hCMV enhancer element, has demonstrated to be a valid 
tissue-specific promoter targeting certain carcinomas, and tissue-specific replication was demonstrated 
in vitro with the muscle-specific SM22 promoter. Combining a tissue specific pEPIto vector system with 
appropriate delivery systems will lead to higher tissue-specificity, diminishing undesired consequences 
and proving to be suitable for long term transgene expression in vivo within gene therapy. 
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2. Results and Discussion 
2.1. An Episomal Plasmid Can Be Complexed with a Polymer and Delivery Is Enhanced by 
Ultrasound in Skeletal Muscle Cells  
An episomal plasmid was used for gene delivery that contains the CMV enhancer and an elongation 
factor 1 alpha promoter (CMV/EF1a), as well as a reporter gene fusion of enhanced green fluorescent 
protein and firefly luciferase (EGFP:Luc), followed by a scaffold/matrix attachment region (MARS) 
(Figure 1A). Surprisingly to us and others, the MARS region appears to play a role in long term gene 
expression in muscle. Another group has reported long-term expression from an earlier version of the 
episome vector (pEPI1-luc) in muscle. They showed data for persistent luciferase expression for 
~84 days from the episome and no expression for a traditional vector [5]. It is possible that the advantage 
of the MARS element in muscle is not the replication ability per se, as it is a post-mitotic structure, but 
rather that the pEPI is less toxic and/or modulates less immune modulation, enabling preservation in 
muscle fibers for a significantly longer time than a traditional plasmid.  
We utilized a polymer with a comb architecture, which efficiently complexes plasmid DNA for gene 
delivery. This type of polymer, has PKKKRKV heptapeptide nuclear localization signal (NLS) 
sequences to provide a branched poly(cyclooctene-graft-oligopeptide) or NLS2, which enhances gene 
delivery in the presence of ultrasound [2] (Figure 1B). We have found that ultrasound stimuli can help 
enhance gene delivery of this nanoplex (pDNA:NLS2) to muscle cells in the presence of microbubbles 
that induce cavitation (Figure 1C). In this study, we have examined the efficiency of transfection of the 
NLS2 in skeletal muscle cells, C2C12 (Figure 1D), and observed that although ultrasound (US) greatly 
augments the efficiency of commercial transfection reagents lipofectamine 2000 (L2K) or naked DNA, 
the effect of US on NLS2 transfection efficiency is enhanced by a further two-fold compared to L2K  
(*, p < 0.05 compared to no ultrasound controls for each group). These results suggested that ultrasound, 
combined with the NLS2 polyplex can be a very useful method of gene delivery for plasmid DNA in 
muscle cells. 
2.2. Sonodelivery of pEPIto-Luc in Vivo Yields Long-Term Gene Expression in Skeletal Muscle 
We next examined ultrasound-assisted or sonodelivery of the NLS2:pDNA nanoplexes in vivo by 
using either pCpGF or pEPIto vectors expressing the reporter gene luciferase. Ultrasound stimuli (+US) 
enhanced the transfection efficiency to hind thigh skeletal muscle for both vectors by day 6 (Figure 2A), 
although pEPIto was able to enable luciferase expression at higher absolute levels compared to pCpGF 
(p/sec/cm2/sr; *, p < 0.05) (Figure 2B). We also were able to examine expression over time, from day 6 
to past 12 months of age. While pEPIto supported expression of luciferase up do day 285 (~9.5 months), 
the pCpGF vector only supported detectable reporter gene expression up to ~day 21 (Figure 2B). These 
results indicated that pEPIto can support long-term expression of a reporter gene, which should enable 
sustained gene therapy efforts for controlling systemic conditions such as metabolic defects or  
bone-metastatic cancers. 
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Figure 1. (A) pEPIto-Luc, containing a cytomegalovirus (CMV) enhancer and an elongation 
factor 1 alpha (EF1a) promoter driving expression of an enhanced green fluorescent protein 
andfirefly luciferase fusion gene (EGFP:Luc). The plasmid is maintained as an episome due 
to the presence of a scaffold/matrix attachment region (MARS) which follows the Luc 
coding region in the absence of a termination signal. (B) The NLS2 polymer used for gene 
delivery in vivo. The polymer is composed of a poly(cyclooctene-graft-oligopeptide) comb 
or branched structure which enhances DNA complexation and release once inside cells.  
(C) The sonodelivery system. A nanoplex is delivered to skeletal muscle via complexation 
of the NLS2 polymer with the pEPIto-Luc plasmid, then delivered through microbubble-assisted 
sonoporation via ultrasound stimulation. The nanoplexes enter the muscle and are 
transported to the nucleus through the NLS moiety in the polymer. (D) Transfection of 
C2C12 skeletal muscle cells is significantly enhanced by ultrasound (+US) compared to each 
-US control for naked, lipofectamine 2000 (L2K) and NLS2 reagents, but not PEI (*, p < 0.05).  
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Figure 2. (A) Sonodelivery of pEPIto-Luc in vivo; (B) Quantification of pEPIto-Luc 
sonodelivery in vivo over time. Signals detected using IVIS Xenogen and presented in 
p/sec/cm2/sr. *, p < 0.05 relative to pCpGF control values at each time point measured. 
2.3. pEPIto Does Not Promote an Inflammatory Response in Muscle Following Sonodelivery 
As assessed by gene expression and histology analyses, pEPIto administration does not appear to 
promote an inflammatory response in skeletal muscle in vivo. These observations compared pEPIto with 
phosphate-buffered saline control (PBS), polymer (NLS), or pCpGF. We selected genes that encode 
signaling molecules previously linked with potential inflammatory responses to plasmid DNA [6], including 
interferon (IFN) response factor (IRF) transcription factors that orchestrate the innate immune response 
as well as other genes related to the upregulation of other immune system elements such as chemokines. 
Quantitative real-time PCR (qPCR) showed that compared to PBS control, the NLS2 polymer mostly 
down regulated the expression of genes associated with an inflammatory response in skeletal muscle. 
For example, polymer alone down regulated genes associated with innate immune signaling (IRF7), IFN 
response (LigP), and chemokines (CXCL9 and 10) (Figure 3A). However, polymer upregulated 
Asc/PYCARD, a gene of the innate immune system responsible for assembly of large signaling 
complexes in inflammatory pathways. Surprisingly, pEPIto had a more favorable profile concerning 
inflammatory gene expression signature than a traditional, pCpG-free (pCpGF) vector (Figure 3A). 
pCpGF upregulated all inflammation-related genes examined with the exception of PYCARD. pEPIto, 
on the other hand, down regulated CXCL9, PYCARD, and LigP genes, while the expression of IRF7 
and CXCL10 remained unchanged relative to PBS control. These results would suggest that the pEPIto 
might be preferable to pCpG free vectors, which appear to induce a variety of pathways related to an 
inflammatory response. 
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The morphology of skeletal muscle was assessed at day 7, 23, and at endpoint, i.e., ~12 months  
post-sonodelivery (Figure 4A,B). Analyses of percentage of H&E stained muscle fibers displaying 
atypical central nuclei show no significant differences (p > 0.3) for either plasmid group for all time 
points (Figure 4C). Neither pCpGF nor pEPIto produced any local or systemic signs of prior or existing 
damage. This data would suggest that this vector and mode of delivery might be relatively safe and 
potentially translatable to clinical studies that require long-term gene expression. Additionally, the pEPIto 
vector may be a viable alternative to viral vectors, which have the disadvantages of requiring integration 
into the genome for sustained gene expression, and may promote inflammation within muscle [7]. 
(A) (B) 
Figure 3. In vivo delivery of pEPIto in skeletal muscle promotes gene expression changes 
but these are consistent with a reduced inflammatory response by day 7 and day 23  
post-delivery as compared to pCpGF control. (A) p < 0.05 relative to all other groups;  
(B) p < 0.05 relative to phosphate-buffered saline control (PBS) (ANOVA).  
3. Experimental Section  
3.1. Vectors 
Plasmid DNA vectors included pEPIto (PlasmidFactory, Bielefeld, Germany) or pCpGFree-mcs 
(pCpGF) (Invivogen, San Diego, CA, USA) backbones expressing firefly luciferase and green 
fluorescent protein genes (Luc, GFP). The Luc-GFP cassette was cloned by PCR cloning into pCpGF 
using NheI and BglII ends in order to produce the same expression cassette (CMV enhancer and EF1 
promoter) in pCpGF. Vectors were prepared for all experiments using Endofree kits (Qiagen, Valencia, 
CA, USA). For efficient complexation with polymer, vectors were first precipitated and resuspended in 
water. Briefly, precipitation used 1:10 volume 3M NaOAc and 2 volumes of cold 100% Ethanol, 
followed by a 30 min incubation at −80 °C and centrifugation at 12,000 rpm for 15 min at 4 °C, and a 
wash using 2 volumes of 70% Ethanol with a 5 min spin at room temp. The pellet was allowed to dry 
and was resuspended in sterile nuclease free water. 
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3.2. In Vivo Studies 
Animal care and procedures were performed in accordance with the UTMB institutional review board 
guidelines. For gene delivery, we used a polymer containing the Simian Virus SV40 nuclear localization 
signal (NLS) NLS2, a comb shaped polymer with a polycyclooctene backbone and tetralysine and NLS 
oligopeptide pendent groups (~50 mol% of each oligopeptide). The synthesis of NLS2 is described in [1]. 
We prepared polymers in low retention Eppendorf tubes, dissolved in nuclease-free water, and sterilized 
by filtration. The stock solution of NLS2 was diluted to enable complexation with pLuc plasmid DNA 
at an N/P ratio = 6. The ratio of protonatable nitrogens in the polymer, N, to DNA phosphates, P). The 
protonatable nitrogens are the amines in the polymer pendent chains, distinct from the amide nitrogens 
of the polypeptide chain that are not protonatable under these conditions. DNA (12.5 μg) was added to 
nuclease-free water 1:1 to polymer solution and allowed to equilibrate for a minimum of 35 min under 
sterile conditions. Following polyplex formation, 5.5% sterile Micromarker microbubbles 
(VisualSonics, Toronto, ON, Canada) were added per tube and injected intramuscularly in 50 μL to the 
hind legs of anesthetized C57/BL6 8-week-old male mice (5 per group). After applying ultrasound gel, 
we irradiated the muscle to mediate sonoporation and thus gene delivery of Luc plasmids using a 
Sonigene sonoporator (VisualSonics) using settings of 1 MHz, 20% duty cycle, 3 W/cm2, 60 s. In vivo 
imaging for luciferase expression in muscle was performed starting on day 6 following sonoporation 
using previously published procedures by intravenous luciferin substrate administration and collection 
of images within 10–20 min [8,9]. 
3.3. Real-Time Quantitative RT-PCR (qPCR) Analyses 
Total RNA from 10–30 mg muscle isolated from the mouse hind thigh was extracted using polytron 
homogenization in Trizol as described [10], followed by purification using a SurePrep kit (FisherSci). 
One microgram of RNA was reverse-transcribed using amfiRivert Platinum cDNA Synthesis Master 
Mix (GenDEPOT, Barker, TX, USA). Real-time qPCR reactions contained 1 µL cDNA template,  
2× SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA), and 10 µM forward and 
reverse primers for both experimental and β-actin controls. qRT-PCR was performed on an Eppendorf 
Realplex 2S (Eppendorf, Hauppauge, NY, USA), using: 40× 95 °C for 3 min; 95 °C for 3 s; 60 °C 30 s; 
72 °C 8 s and analyzed using EP Realplex software (Ver. 2.2).  
3.4. Histology 
Hind thigh muscles were fixed overnight in 10% buffered formalin (Fishersci), then embedded in 
paraffin and sectioned (5 μm). Sections were stained with hematoxylin and eosin and imaging was 
performed using a photomicroscope at the Research Histopathology Core.  
3.5. Statistical Analysis 
Quadruplicate wells were used in real time PCR analyses and experiment repeated twice, with values 
provided as mean ± SEM or 95% confidence interval. Comparisons for transfection data were performed 
using an unpaired t-test, and p < 0.05 was considered to indicate a significant difference. Comparisons 
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for the real-time PCR gene expression data used one-way ANOVA analyses with α = 0.05, with a Tukey’s 
test for pairwise comparison of group means. 
 
Figure 4. Histological analyses at day 7, 23, and 12 months indicate neither pCpGF (A) nor 
pEPIto (B) produce any significant signs of damage, as shown by H&E staining and 
visualization of skeletal muscle at 200x magnification. Inset, selected areas at higher 
magnification to show nuclear positioning in muscle fibers. Scale bar, 50 μm. Arrows, 
normal positioning of nuclei at the periphery of muscle fibers (F); arrowheads, occasional 
atypical nuclei positioned centrally within fibers. (C) Analyses of percentage of muscle 
fibers displaying atypical central nuclei show no significant differences (p > 0.3) for either 
plasmid group for all three time points. 
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4. Conclusions  
Most recently, a tissue-specific episomal version of pEPI has been described [11] that has high 
promise for extending the applications of present vectors towards more efficient gene therapy and gene 
delivery applications. The delivery system and vector described herein promise to advance the field of 
sonodelivery and of muscle gene delivery for therapeutic applications. A simple approach is shown 
which can achieve long-term gene expression in vivo with the promise of a minimal profile of 
inflammatory gene expression. Episomal vectors based on pEPI have continued to be refined and we 
envision that episomal vectors will have applications for replicating in a tissue specific manner. 
Combining a tissue specific pEPIto vector system with appropriate delivery systems will lead to higher 
tissue-specificity, diminishing undesired consequences and proving to be suitable for long term 
transgene expression in vivo within gene therapy. 
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